Octapharma's therapy for von Willebrand disease gets orphan drug designation
This article was originally published in Scrip
Executive Summary
The US FDA has granted orphan drug exclusivity to Octapharma's Wilate for the treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD), as well as in patients with mild or moderate VWD for whom the use of desmopressin is known or suspected to be ineffective or contraindicated.